Health
Roche, BioNTech post ‘low’ response rate in cancer vaccine trial – FierceBiotech
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a “low” response rate. Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers po…
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a low response rate. Nine of the 108 evaluable solid tumor patients responded when given the vacc…
-
Noosa News9 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General15 hours agoBoy dies after being trapped between rocks off NSW beach
-
Noosa News16 hours agoFarmer Fred Perry’s 30-year conservation project creates bird haven after years of ‘bashing and burning’
-
Noosa News16 hours agoDetectives continue to search for answers on Crystal Beale’s death